653522fe-3289-4e1f-9373-c81f923893a3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- ALLOGRAFT_REJECTION+0.400
- TGF_BETA_SIGNALING+0.400
- UV_RESPONSE_DN+0.400
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.300
- COMPLEMENT+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.400
- MYC_TARGETS_V1-0.400
- MYC_TARGETS_V2-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- DNA_REPAIR-0.300
- MTORC1_SIGNALING-0.300
- GLYCOLYSIS-0.200
- PANCREAS_BETA_CELLS-0.200
- SPERMATOGENESIS-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6943-01A-11R-1915-07 | — | — | 0.926 |
| 2 | TCGA-CN-5373-01A-01R-1436-07 | — | — | 0.911 |
| 3 | TCGA-CR-7376-01A-11R-2132-07 | — | — | 0.910 |
| 4 | TCGA-CR-7392-01A-11R-2016-07 | — | — | 0.910 |
| 5 | SRR5088824 | — | — | 0.910 |
| 6 | TCGA-CR-7394-01A-11R-2016-07 | — | — | 0.908 |
| 7 | TCGA-CN-4733-01A-02R-1873-07 | — | — | 0.903 |
| 8 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.900 |
| 9 | BS_69V8P8A0 | Neurofibroma | — | 0.896 |
| 10 | TCGA-AC-A2B8-01A-11R-A17B-07 | — | A | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |